FDA clears GRI Bio’s Phase 2 trial of natural killer T-cell targeted therapy

Immune NK T-cells may be therapeutic target for IPF

Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…

First patient enrolled in TETON PPF study of nebulized Tyvaso

The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…

This veteran provided me inspiration on this PF journey

Veterans Day is approaching on Nov. 11, and most of us know someone who served in the military. For this column, I’d like to honor someone who left behind some promising words of the highest degree. During a recent conversation, the person I was chatting with brought up my…